Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Dortmund – page 28

1 507 clinical trials in Dortmund, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Dortmund at a glance
1 507
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

1 507 trials in Dortmund

Open in trial search

Study of human normal immunoglobulin and teclistamab for infection prevention in adults with multiple myeloma receiving B-cell maturation antigen therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Takeda Development Center Americas Inc.

Study of Rilvegostomig with Bevacizumab and Tremelimumab as First-line Treatment for Patients with Advanced Liver Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:AstraZeneca AB

Study comparing RMC-6236 and docetaxel in previously treated patients with advanced or metastatic non-small cell lung cancer who have RAS mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rilzabrutinib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of BMS-986368 to treat muscle stiffness in people with Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:CC-97489
  • Sponsor:Celgene Corp.

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Daiichi Sankyo Inc.

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study of visugromab and nivolumab with or without docetaxel as second-line treatment for patients with metastatic non-squamous non-small cell lung cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:CatalYm GmbH

Constipation

Recruiting

Safety and tolerability study of sodium hydrogen carbonate and sodium dihydrogen phosphate suppository treatment in adult patients with chronic constipation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sodium dihydrogen phosphate
  • Sponsor:Athenstaedt GmbH & Co. KG

Study of Darolutamide and Testosterone for Patients with Advanced Prostate Cancer Resistant to Standard Hormone Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Universitaet Muenster

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Dortmund

What the registry says about research in the country

01 Oncology Research

Groundbreaking clinical trials focusing on various cancer types, including lymphomas, breast cancer, and hepatic tumors. Studies evaluate novel treatment combinations and personalized approaches.

  • Chronic Lymphocytic Leukemia Studies
  • Advanced Breast Cancer Treatments
  • Pediatric Liver Cancer Research

Innovative protocols combining immunotherapy with conventional treatments to improve patient outcomes.

02 Cardiovascular Medicine

Extensive research into cardiovascular diseases, focusing on preventive treatments and management of acute conditions. Studies examine new approaches to reduce major cardiac events.

  • Atherosclerotic Disease Management
  • Post-Heart Attack Interventions
  • Stroke Prevention Studies

Novel therapies targeting lipid management and cardiovascular risk reduction.

03 Neurological Disorders

Clinical investigations focusing on multiple sclerosis and other neurological conditions. Studies evaluate new treatment options and disease-modifying therapies.

  • Relapsing Multiple Sclerosis Treatments
  • Cognitive Function Studies
  • Novel Therapeutic Approaches

Research aims to improve patient outcomes through innovative treatment strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.